Market revenue in 2023 | USD 434.0 million |
Market revenue in 2030 | USD 395.1 million |
Growth rate | -1.3% (CAGR from 2023 to 2030) |
Largest segment | Antiemetics |
Fastest growing segment | NSAIDs and Others |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 26.2% in 2023. Horizon Databook has segmented the Middle East & Africa cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Middle Eastern countries, such as Saudi Arabia, Qatar, United Arab Emirates (UAE), Kuwait, and Oman, are prospering economies. Advancements in healthcare systems are expected to increase the demand for cancer supportive care drugs in this region. On the contrary, some countries in the African region lack adequate healthcare infrastructure.
However, in coordination with WHO or other independent organizations, governments of these countries are undertaking several initiatives for advancement of healthcare sector in the region. This is expected to help in development of the market in the near future. However, the availability of generic and biosimilar drugs is expected to impede market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cancer supportive care drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account